EU approves Merck & Co's Sycrest for bipolar disorder
This article was originally published in Scrip
Executive Summary
The EMA has approved Merck & Co's Sycrest (asenapine) for the treatment of manic episodes in bipolar 1 disorder in adults. The atypical antipsychotic was approved for manic episodes associated with bipolar 1 disorder, and for schizophrenia, in the US last year, where it is marketed as Saphris (scripintellingence, 14 August 2009).